Biotech Values

[DewDiligence]

Re: Potential LLY/EGRX partnership on Alimta

I assume there's a possibility EGRX partners with Lilly with a deal similar to their deal with TEVA for Bendeka?

The situation is similar but not identical. LLY has a stronger hand with Alimta than TEVA had with Treanda insofar as LLY’s 7772209 patent, which runs until May 2022, was found valid by the US District Court (#msg-99866629), and hence LLY does not need to contend with competition from full-fledged Alimta generics in the US market for several years.

When EGRX obtains FDA approval for RTU Alimta, LYY may decide to sue EGRX to try to maintain full exclusivity rather than partnering with EGRX and implementing a “hard switch” from regular Alimta to the RTU product.

If LLY does sue, a settlement is pretty likely, IMO. (EGRX’s Bendeka partnership with TEVA arose from a patent settlement.)